Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation.

Autor: Kong LR; Cancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore. csiklr@nus.edu.sg.; Medical Research Council Cancer Unit, University of Cambridge, Cambridge, CB2 0XZ, UK. csiklr@nus.edu.sg., Ong RW; Laboratory of Molecular Endocrinology, National Cancer Centre Singapore, Singapore, Singapore., Tan TZ; Cancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore., Mohamed Salleh NAB; Cancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore., Thangavelu M; Genome Institute of Singapore, Agency for Science, Technology & Research (A*STAR), Singapore, 138672, Singapore., Chan JV; Genome Institute of Singapore, Agency for Science, Technology & Research (A*STAR), Singapore, 138672, Singapore., Koh LYJ; Genome Institute of Singapore, Agency for Science, Technology & Research (A*STAR), Singapore, 138672, Singapore., Periyasamy G; Genome Institute of Singapore, Agency for Science, Technology & Research (A*STAR), Singapore, 138672, Singapore., Lau JA; Cancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore., Le TBU; Laboratory of Molecular Endocrinology, National Cancer Centre Singapore, Singapore, Singapore., Wang L; Cancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore.; Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117597, Singapore., Lee M; Medical Research Council Cancer Unit, University of Cambridge, Cambridge, CB2 0XZ, UK., Kannan S; Bioinformatics Institute, Agency for Science, Technology, and Research (A*STAR), Singapore, 138671, Singapore., Verma CS; Bioinformatics Institute, Agency for Science, Technology, and Research (A*STAR), Singapore, 138671, Singapore.; Department of Biological Sciences, National University of Singapore, Singapore, 117558, Singapore.; School of Biological Sciences, Nanyang Technological University, Singapore, 639798, Singapore., Lim CM; Division of Surgical Oncology (Head and Neck Surgery), National University Cancer Institute, Singapore (NCIS), Singapore, 119074, Singapore., Chng WJ; Cancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore.; Department of Haematology-Oncology, National University Cancer Institute, Singapore, 119074, Singapore.; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119228, Singapore., Lane DP; p53 Laboratory (p53Lab), Agency for Science, Technology, and Research (A*STAR), Singapore, 138648, Singapore., Venkitaraman A; Medical Research Council Cancer Unit, University of Cambridge, Cambridge, CB2 0XZ, UK., Hung HT; Laboratory of Molecular Endocrinology, National Cancer Centre Singapore, Singapore, Singapore., Cheok CF; Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology, and Research (A*STAR), Singapore, 138673, Singapore.; Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119074, Singapore.; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117596, Singapore., Goh BC; Cancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore. phcgbc@nus.edu.sg.; Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117597, Singapore. phcgbc@nus.edu.sg.; Department of Haematology-Oncology, National University Cancer Institute, Singapore, 119074, Singapore. phcgbc@nus.edu.sg.

Publikováno v: Nature communications [Nat Commun] 2020 Apr 29; Vol. 11 (1), pp. 2086. Date of Electronic Publication: 2020 Apr 29.